Nearly 40,000 Bottles of Clear Eyes Eye Drops Recalled Due to Sterility Concerns

Introduction

A significant recall has been issued for a popular over-the-counter eye care product, impacting nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief. The voluntary recall, initiated by manufacturer Prestige Brands Holdings, stems from concerns regarding the product's sterility. While the company states that no contamination has been confirmed and no serious adverse events have been reported, the precautionary measure highlights the critical importance of maintaining sterility in ophthalmic products.

Key Details

• Product Recalled: Clear Eyes Maximum Itchy Eye Relief
• Manufacturer: Prestige Brands Holdings, Tarrytown, New York
• Quantity Recalled: 39,060 bottles
• Reason for Recall: Lack of assurance of sterility
• Affected Lot: 2552A
• Expiration Date: September 30, 2027
• Product Size: 0.5-ounce (15-milliliter) dropper bottles
• Retailers: Sold at major retailers including Walmart
• Product Identifiers: NDC 67172-999-01, UPC 6 78112 65920 3
• Recall Classification: Class II (issued August 14, 2026)
• Reported Side Effects: None confirmed as serious as of August 23, 2026

Background

The U.S. Food and Drug Administration (FDA) announced the recall, which began on July 29, 2026, and was still in progress at the time of reporting. The specific reason cited by the FDA is a “lack of assurance of sterility.” A spokesperson for Prestige Brands Holdings, Phil Terpolilli, confirmed to The New York Times that potential contamination was identified during the production process. However, details regarding the nature of this potential contamination were not disclosed by either the company or the FDA. Terpolilli emphasized that the recall was an “abundance of caution” and that the product was never confirmed to be contaminated. Importantly, he also stated that no other Clear Eyes products are affected by this recall.

Impact Analysis

The FDA's classification of this recall as Class II is significant. This designation indicates that the product could cause temporary or reversible health problems, and the likelihood of serious adverse events is considered remote. This classification suggests that while the sterility concern is taken very seriously, the immediate risk to consumers is assessed as low. However, any breach in sterility for ophthalmic products is a critical concern due to the direct application to the sensitive eye tissues. Potential contamination could lead to infections, inflammation, or other adverse reactions, even if they are temporary or reversible.

“The company acted out of an abundance of caution,” said Phil Terpolilli, a spokesman for the manufacturer, Prestige Brands Holdings. He added that the drops were never confirmed to be contaminated.

Broader Context

This recall is not an isolated incident in the eye care industry. It follows a much larger recall in March 2026, when K.C. Pharmaceuticals Inc. voluntarily withdrew over 3 million bottles of various eye drops, including artificial tears, lubricating drops, and redness relievers. These products were sold under multiple store brands at major retailers. That recall, also classified as Class II, was similarly attributed to a lack of assurance of sterility. The recurrence of such recalls, even for different manufacturers, underscores potential systemic challenges in ensuring the sterility of widely distributed ophthalmic solutions. While eye drop recalls are less frequent than those for other pharmaceuticals or consumer goods, these events raise important questions about manufacturing standards and quality control within the sector.

Future Outlook

The current recall serves as a stark reminder for both manufacturers and consumers. For Prestige Brands Holdings, the focus will be on thoroughly investigating the root cause of the sterility concern to prevent future occurrences and to reassure consumers and regulators of their commitment to product safety. For consumers, the incident reinforces the importance of being aware of product recalls and following manufacturer and regulatory guidance. The FDA will likely continue to monitor manufacturing practices closely. The broader industry may see increased scrutiny and potentially updated guidelines or inspection protocols to further safeguard the sterility of eye care products, ensuring that such essential items remain safe for their intended use.

Conclusion

The recall of Clear Eyes Maximum Itchy Eye Relief highlights the paramount importance of sterility in ophthalmic products. While the immediate health risk appears low, the precautionary recall by Prestige Brands Holdings underscores a commitment to consumer safety. Consumers possessing the affected lot are advised to cease use and return the product for a refund. This event, alongside previous recalls in the sector, emphasizes the ongoing need for rigorous quality control and adherence to sterile manufacturing practices in the pharmaceutical industry to protect public health.